- Home
- ASBP vs HOTH Comparison
ASBP vs HOTH Comparison
Compare ASBP & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | HOTH |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASBP | HOTH |
|---|---|---|
| Price | $0.10 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 67.6M | 256.5K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.66 |
| 52 Week High | $15.80 | $3.80 |
Technical Indicators
Market Signals| Indicator | ASBP | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 39.83 |
| Support Level | $0.10 | $1.14 |
| Resistance Level | $0.11 | $1.24 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 19.29 | 44.67 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).